When will bioprinting become a therapy? Translational and regulatory challenges in urogenital tissue engineering and surgery
Margrethe Ruding, Amitha Banu Shajahan, Magdalena Fossum, Cristian Pablo Pennisi, Johan Ulrik Lind · 2026
Read When will bioprinting become a therapy? Translational and regulatory challenges in urogenital tissue engineering and surgery by Margrethe Ruding, Amitha Banu Shajahan, Magdalena Fossum, Cristian Pablo Pennisi, Johan Ulrik Lind (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13518311.txt.
Description
d early-stage trials (ACTRN12625000088448, 2026; CTRI/2024/11/077162, 2026; CTRI/2024/12/078592, 2026; NCT04925323, 2026; NCT06051747, 2026). This is particularly true within urethral and urogenital tissue engineering and surgery where bioprinted constructs may fall into a “grey zone” between medical devices and advanced biologics. Thus, while several bioprinting strategies have shown promise for bioprinting urinary and genital tissues in the lab (Kim et al.
Catalog record
| CREATOR | Margrethe Ruding, Amitha Banu Shajahan, Magdalena Fossum, Cristian Pablo Pennisi, Johan Ulrik Lind |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |